Prevail therapeutics inc. (PRVL)
Income statement / Yearly
Dec'19Dec'18
Operating Expenses:
Research and development

48,798

14,127

General and administrative

17,005

4,682

Operating loss

-65,803

-18,809

Change in fair value of derivative liabilities

-

781

Other income

-

87

Interest income

2,615

887

Interest expense

-

471

Total other income

2,615

-278

Net loss

-63,188

-19,087

Net loss per share
Basic and Diluted

-2.22

-3.71

Weighted average shares outstanding:
Basic and Diluted

28,494

5,145